Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country

The objective of the present study was to determine the efficacy of detection of antigliadin immunoglobulins G and A (IgG and IgA) for the diagnosis of celiac disease in a developing country, since other enteropathies might alter the levels of these antibodies. Three groups were studied: 22 patients...

Full description

Bibliographic Details
Main Authors: M. Bahia, A. Rabello, G. Brasileiro Filho, F.J. Penna
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2001-11-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001100007
id doaj-97cde98bbe944f638bd0ede8e283bbcf
record_format Article
spelling doaj-97cde98bbe944f638bd0ede8e283bbcf2020-11-24T22:27:53ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2001-11-0134111415142010.1590/S0100-879X2001001100007Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing countryM. BahiaA. RabelloG. Brasileiro FilhoF.J. PennaThe objective of the present study was to determine the efficacy of detection of antigliadin immunoglobulins G and A (IgG and IgA) for the diagnosis of celiac disease in a developing country, since other enteropathies might alter the levels of these antibodies. Three groups were studied: 22 patients with celiac disease (mean age: 30.6 months), 61 patients with other enteropathies (mean age: 43.3 months), and 46 patients without enteropathies (mean age: 96.9 months). Antigliadin IgG and IgA ELISA showed sensitivity of 90.9 and 95.5%, respectively. With the hypothetical values of prevalence ranging from 1:500 to 1:2000 liveborns, the positive predictive value varied from 8.5 to 2.3% for IgG and from 4.8 to 1.1% for IgA. Considering the patients without enteropathies, specificity was 97.8 and 95.7% for IgG and IgA, respectively. In patients with other enteropathies, specificity was 82.0 and 84.1%, respectively. When patients with and without other enteropathies were considered as a whole, specificity was 88.8 and 91.6%, respectively. The specificity of positive IgG or IgA was 93.5% in children without enteropathies and 78.7% in the presence of other enteropathies. The negative predictive value for hypothetical prevalences varying from 1:500 to 1:2000 liveborns was 99.9%. Thus, even in developing countries where the prevalence of non-celiac enteropathies is high, the determination of serum antigliadin antibody levels is a useful screening test prior to the jejunal biopsy in the investigation of intestinal malabsorption.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001100007celiac diseaseenteropathiesantigliadin antibodies
collection DOAJ
language English
format Article
sources DOAJ
author M. Bahia
A. Rabello
G. Brasileiro Filho
F.J. Penna
spellingShingle M. Bahia
A. Rabello
G. Brasileiro Filho
F.J. Penna
Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
Brazilian Journal of Medical and Biological Research
celiac disease
enteropathies
antigliadin antibodies
author_facet M. Bahia
A. Rabello
G. Brasileiro Filho
F.J. Penna
author_sort M. Bahia
title Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
title_short Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
title_full Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
title_fullStr Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
title_full_unstemmed Serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
title_sort serum antigliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country
publisher Associação Brasileira de Divulgação Científica
series Brazilian Journal of Medical and Biological Research
issn 0100-879X
1414-431X
publishDate 2001-11-01
description The objective of the present study was to determine the efficacy of detection of antigliadin immunoglobulins G and A (IgG and IgA) for the diagnosis of celiac disease in a developing country, since other enteropathies might alter the levels of these antibodies. Three groups were studied: 22 patients with celiac disease (mean age: 30.6 months), 61 patients with other enteropathies (mean age: 43.3 months), and 46 patients without enteropathies (mean age: 96.9 months). Antigliadin IgG and IgA ELISA showed sensitivity of 90.9 and 95.5%, respectively. With the hypothetical values of prevalence ranging from 1:500 to 1:2000 liveborns, the positive predictive value varied from 8.5 to 2.3% for IgG and from 4.8 to 1.1% for IgA. Considering the patients without enteropathies, specificity was 97.8 and 95.7% for IgG and IgA, respectively. In patients with other enteropathies, specificity was 82.0 and 84.1%, respectively. When patients with and without other enteropathies were considered as a whole, specificity was 88.8 and 91.6%, respectively. The specificity of positive IgG or IgA was 93.5% in children without enteropathies and 78.7% in the presence of other enteropathies. The negative predictive value for hypothetical prevalences varying from 1:500 to 1:2000 liveborns was 99.9%. Thus, even in developing countries where the prevalence of non-celiac enteropathies is high, the determination of serum antigliadin antibody levels is a useful screening test prior to the jejunal biopsy in the investigation of intestinal malabsorption.
topic celiac disease
enteropathies
antigliadin antibodies
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001100007
work_keys_str_mv AT mbahia serumantigliadinantibodylevelsasascreeningcriterionbeforejejunalbiopsyindicationforceliacdiseaseinadevelopingcountry
AT arabello serumantigliadinantibodylevelsasascreeningcriterionbeforejejunalbiopsyindicationforceliacdiseaseinadevelopingcountry
AT gbrasileirofilho serumantigliadinantibodylevelsasascreeningcriterionbeforejejunalbiopsyindicationforceliacdiseaseinadevelopingcountry
AT fjpenna serumantigliadinantibodylevelsasascreeningcriterionbeforejejunalbiopsyindicationforceliacdiseaseinadevelopingcountry
_version_ 1725748520984510464